RenovoRx's Upcoming Presentations at Major Conferences
RenovoRx, Inc. (Nasdaq: RNXT), based in Mountain View, California, is making strides in the field of oncology with the announcement of three accepted abstracts for presentation at renowned industry conferences. These presentations will take place at significant events including the ASCO Gastrointestinal Cancers Symposium 2025, Society of Interventional Oncology (SIO) 2025, and Society of Surgical Oncology (SSO) 2025. The company is focused on developing groundbreaking cancer therapies, utilizing their FDA-cleared RenovoCath platform for targeted delivery.
Innovative TAMP Therapy Platform
RenovoRx’s TAMP (Trans-Arterial Micro-Perfusion) therapy platform is at the core of their innovative approach to cancer treatment. This platform involves precise delivery of therapeutic agents directly to tumor sites via the arterial route. The recent acceptance of abstracts highlights significant advancements in their Phase III clinical trial and the underlying pharmacokinetic studies supporting the efficacy and safety of the treatment.
Key Abstracts and Their Contributions
The abstracts being presented detail the capabilities of RenovoRx’s TAMP therapy, showcasing both human pharmacokinetic (PK) data and pre-clinical findings. The focus on enhancing drug concentration at tumor sites while reducing overall toxicity as compared to traditional intravenous therapies is a key theme. The acceptance of these abstracts is a testament to the promising data emerging from RenovoRx's ongoing clinical trials.
Insights on the TIGeR-PaC Clinical Trial
One of the highlighted pieces of research pertains to the TIGeR-PaC clinical trial, which is evaluating RenovoRx’s innovative oncology drug-device combination. This trial studies the application of gemcitabine using the RenovoCath device for intra-arterial administration, aiming to enhance therapeutic effects while minimizing side effects. Completion of patient enrollment is anticipated in the first half of 2025, with the next interim analysis expected shortly thereafter.
Details of Upcoming Abstract Presentations
In preparation for these notable conferences, RenovoRx has outlined details for their abstract presentations:
ASCO GI 2025
Title: Intra-arterial Gemcitabine Versus Intravenous Gemcitabine: Pharmacokinetic Sub-study of the TIGeR-PaC Phase 3 Clinical Trial
Authors: Paula Novelli MD and colleagues
Location: Moscone West, San Francisco
Date/Time: January 24, 2025, at 11:30 a.m. PT
SIO 2025
Title: Micro-CT Imaging Following Intra-arterial Delivery in a Preclinical Model
Authors: Paula Novelli MD and colleagues
Location: Horseshoe Las Vegas, Las Vegas
Date/Time: February 2, 2025, at 12:30 p.m. PT
SSO 2025
Title: Pharmacodynamics of Intra-arterial vs. Intravenous Gemcitabine in Advanced Pancreatic Cancer
Authors: Emmanuel Zervos MD and colleagues
Location: Tampa Convention Center
Dates: March 27 – 29, 2025
Empowering Future Oncology Treatments
Dr. Ramtin Agah, Chief Medical Officer and Founder of RenovoRx, emphasized the potential of TAMP therapy to revolutionize cancer treatment standards. The targeted delivery method aims to optimize drug concentration directly at tumor sites, potentially enhancing efficacy while decreasing toxicities associated with conventional therapies. The commitment of RenovoRx to innovate solutions for cancer patients remains steadfast.
As RenovoRx continues its journey through the clinical trial stages, the data presented at these conferences will play a crucial role in illustrating the effectiveness of TAMP therapy. The momentum built from these accepted abstracts underscores the company’s vision and the promising future their technologies have for oncology.
About RenovoRx, Inc.
RenovoRx is dedicated to transforming the landscape of cancer treatment through the development of targeted therapies. The company has pioneered the RenovoCath delivery platform, which is designed to administer chemotherapy effectively while aiming to increase safety and reduce side effects. As the company progresses on its clinical trials, it remains focused on the unique challenges posed by cancer, seeking to cater solutions that address significant medical needs.
Frequently Asked Questions
What is RenovoRx known for?
RenovoRx is recognized for developing targeted oncology therapies and its FDA-cleared RenovoCath delivery platform.
What is the TAMP therapy platform?
The TAMP (Trans-Arterial Micro-Perfusion) therapy platform is designed for the precise delivery of therapeutic agents directly to tumors, minimizing systemic effects.
When are the upcoming presentations scheduled?
The presentations are scheduled for early 2025, with key dates in January, February, and March.
What does the TIGeR-PaC clinical trial focus on?
The TIGeR-PaC clinical trial evaluates the efficacy of gemcitabine administered via the RenovoCath device in patients with advanced pancreatic cancer.
How does RenovoRx aim to impact cancer treatments?
RenovoRx aims to enhance the safety and efficacy of cancer therapies while addressing significant unmet medical needs through innovative delivery methods.
